Literature DB >> 10571970

Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men.

G Nickenig1, A T Bäumer, Y Temur, D Kebben, F Jockenhövel, M Böhm.   

Abstract

BACKGROUND: Hypercholesterolemia causes an upregulation of vascular angiotensin II type 1 (AT1) receptor expression in cell culture and animal models. The presented studies were undertaken to examine AT1 receptor overexpression in hypercholesterolemic men and therapeutic interventions thereof by HMG CoA reductase inhibitors (statins). METHODS AND
RESULTS: Effects of AT1 receptor activation were measured by assessing the blood pressure increase after infusion of angiotensin II in normo- (cholesterol 181+/-11 mg/dL) and hypercholesterolemic (cholesterol 294+/-10 mg/dL) men (n=19 and 20, respectively). AT1 receptor expression was assessed on isolated platelets. Some patients were investigated before and after cholesterol-lowering therapy with statins. Hypercholesterolemia led to a significant increase of angiotensin II-induced blood pressure elevation. AT1 receptor expression was significantly enhanced in hypercholesterolemic individuals (B(max)=5.2+/-1.2 fmol/mg protein) compared with normocholesterolemic men (B(max)=2.1+/-0.2 fmol/mg protein). Cholesterol-lowering treatment with statins reversed the elevated blood pressure response to angiotensin II infusion (P<0.05) and downregulated AT1 receptor density (P<0.05).
CONCLUSIONS: Hypercholesterolemia induces AT1 receptor overexpression and enhances biological effects of angiotensin II in men. These findings provide novel insights into the pathogenesis of hypertension and atherosclerosis and may initiate rational and new therapeutic concepts.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10571970     DOI: 10.1161/01.cir.100.21.2131

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  74 in total

1.  Interaction between blood pressure, lipoproteins, angiotensin, and vascular disease.

Authors:  Aram V Chobanian
Journal:  Curr Hypertens Rep       Date:  2002-04       Impact factor: 5.369

2.  LDL cholesterol angiotensin II interactions in atherosclerosis.

Authors:  F C Luft
Journal:  J Mol Med (Berl)       Date:  2001-05       Impact factor: 4.599

Review 3.  Is fixed combination therapy appropriate for initial hypertension treatment?

Authors:  William J Elliott
Journal:  Curr Hypertens Rep       Date:  2002-08       Impact factor: 5.369

4.  Intensive statin treatment improves baroreflex sensitivity: another cardioprotective mechanism for statins?

Authors:  D Patterson; J B C Dick; A D Struthers
Journal:  Heart       Date:  2002-10       Impact factor: 5.994

5.  Role of the angiotensin II receptor blocker valsartan in heart failure.

Authors:  R L Webb; M de Gasparo
Journal:  Exp Clin Cardiol       Date:  2001

Review 6.  Treatment of multiple-risk patients: using combination therapy to treat beyond LDL lowering.

Authors:  Howard S Weintraub
Journal:  Curr Hypertens Rep       Date:  2005-08       Impact factor: 5.369

Review 7.  Differential metabolic actions of specific statins: clinical and therapeutic considerations.

Authors:  Soo Lim; Ichiro Sakuma; Michael J Quon; Kwang Kon Koh
Journal:  Antioxid Redox Signal       Date:  2013-09-24       Impact factor: 8.401

8.  Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/Amlodipine Combination in Hypertensive Patients with Hypercholesterolemia.

Authors:  Yuriy Sirenko; Ganna Radchenko
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-02-02

Review 9.  Hypertension and the metabolic syndrome.

Authors:  John A Farmer
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

10.  Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia.

Authors:  Chang-Jiang Ge; Shu-Zheng Lu; Yun-Dai Chen; Xiao-Fan Wu; Shen-Jiang Hu; Ying Ji
Journal:  Heart Vessels       Date:  2008-04-04       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.